| Ending the HIV epidemic in the USA: an economic modelling study in six cities B Nosyk, X Zang, E Krebs, B Enns, JE Min, CN Behrends, C Del Rio, ... The Lancet HIV 7 (7), e491-e503, 2020 | 56 | 2020 |
| The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities E Krebs, X Zang, B Enns, JE Min, CN Behrends, C Del Rio, ... Aids 34 (3), 447-458, 2020 | 47 | 2020 |
| Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996–2013: a modelling study B Nosyk, X Zang, JE Min, E Krebs, VD Lima, MJ Milloy, J Shoveller, ... The lancet HIV 4 (7), e303-e310, 2017 | 44 | 2017 |
| Developing a dynamic HIV transmission model for 6 US cities: an evidence synthesis E Krebs, B Enns, L Wang, X Zang, D Panagiotoglou, C Del Rio, ... PloS one 14 (5), e0217559, 2019 | 41 | 2019 |
| “Ending the epidemic” will not happen without addressing racial/ethnic disparities in the United States human immunodeficiency virus epidemic B Nosyk, E Krebs, X Zang, M Piske, B Enns, JE Min, CN Behrends, ... Clinical Infectious Diseases 71 (11), 2968-2971, 2020 | 35 | 2020 |
| Development and calibration of a dynamic HIV transmission model for 6 US cities X Zang, E Krebs, JE Min, A Pandya, BDL Marshall, BR Schackman, ... Medical Decision Making 40 (1), 3-16, 2020 | 33 | 2020 |
| Ending the epidemic in America will not happen if the status quo continues: modeled projections for human immunodeficiency virus incidence in 6 US cities B Nosyk, X Zang, E Krebs, JE Min, CN Behrends, C Del Rio, ... Clinical Infectious Diseases 69 (12), 2195-2198, 2019 | 27 | 2019 |
| The potential epidemiological impact of coronavirus disease 2019 (COVID-19) on the human immunodeficiency virus (HIV) epidemic and the cost-effectiveness of linked, opt-out HIV … X Zang, E Krebs, S Chen, M Piske, WS Armstrong, CN Behrends, ... Clinical Infectious Diseases 72 (11), e828-e834, 2021 | 26 | 2021 |
| Cost-effectiveness of the ‘One4All’HIV linkage intervention in Guangxi Zhuang autonomous region, China X Zang, H Tang, JE Min, D Gu, JSG Montaner, Z Wu, B Nosyk PloS one 11 (11), e0167308, 2016 | 24 | 2016 |
| The potential epidemiological impact of COVID-19 on the HIV/AIDS epidemic and the cost-effectiveness of linked, opt-out HIV testing: A modeling study in six US cities X Zang, E Krebs, S Chen, M Piske, WS Armstrong, CN Behrends, ... Clinical Infectious Diseases 72 (11), ciaa1547-, 2021 | 21 | 2021 |
| The cost-effectiveness of human immunodeficiency virus testing and treatment engagement initiatives in British Columbia, Canada: 2011–2013 B Nosyk, JE Min, E Krebs, X Zang, M Compton, R Gustafson, R Barrios, ... Clinical Infectious Diseases 66 (5), 765-777, 2018 | 21 | 2018 |
| Impact of public hospital pricing reform on medical expenditure structure in Jiangsu, China: a synthetic control analysis X Zang, M Zhang, S Wei, W Tang, S Jiang BMC health services research 19, 1-9, 2019 | 19 | 2019 |
| Incorporating productivity loss in health economic evaluations: a review of guidelines and practices worldwide for research agenda in China S Jiang, Y Wang, L Si, X Zang, YY Gu, Y Jiang, GG Liu, J Wu BMJ Global Health 7 (8), e009777, 2022 | 18 | 2022 |
| Evaluating equity in community-based naloxone access among racial/ethnic groups in Massachusetts S Nolen, X Zang, A Chatterjee, CN Behrends, TC Green, BP Linas, ... Drug and alcohol dependence 241, 109668, 2022 | 17 | 2022 |
| Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts … X Zang, A Macmadu, MS Krieger, CN Behrends, TC Green, JR Morgan, ... International Journal of Drug Policy 98, 103435, 2021 | 17 | 2021 |
| Characterizing human immunodeficiency virus antiretroviral therapy interruption and resulting disease progression using population-level data in British Columbia, 1996–2015 L Wang, JE Min, X Zang, P Sereda, RP Harrigan, JSG Montaner, B Nosyk Clinical Infectious Diseases 65 (9), 1496-1503, 2017 | 17 | 2017 |
| Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities AML Quan, C Mah, E Krebs, X Zang, S Chen, K Althoff, W Armstrong, ... The lancet HIV 8 (9), e581-e590, 2021 | 15 | 2021 |
| Addressing methodological and ethical issues in practicing health economic evaluation in China S Jiang, Z Chen, J Wu, X Zang, Y Jiang Journal of global health 10 (2), 2020 | 10 | 2020 |
| Structural design and data requirements for simulation modelling in HIV/AIDS: a narrative review X Zang, E Krebs, L Wang, BDL Marshall, R Granich, BR Schackman, ... PharmacoEconomics 37, 1219-1239, 2019 | 10 | 2019 |
| Community‐based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island S Nolen, X Zang, A Chatterjee, CN Behrends, TC Green, A Kumar, ... Addiction 117 (5), 1372-1381, 2022 | 9 | 2022 |